Oral Contraceptives and BRCA Cancer: A Balancing Act
A partir d'un modèle de simulation incluant 10 000 personnes porteuses de la mutation BRCA1 et 10 000 personnes porteuses de la mutation BRCA2, cette étude analyse, selon 18 scénarios, l'association entre une utilisation de contraceptifs oraux combinés et le risque de cancer du sein, de l'ovaire et de l'endomètre
Women who inherit a pathogenic mutation in the BRCA1 or BRCA2 gene face high lifetime risks of developing breast and ovarian (or fallopian tube) cancer. It is suggested that these women are also predisposed to endometrial cancer (particularly the aggressive serous subtype), albeit with a much lower risk than that of breast or ovarian cancer. The impact of modifiable exposures on cancer risk, particularly exogenous hormones, including oral contraceptives and hormone replacement therapy (HRT), have been studied extensively. They contain similar hormone profiles, although the doses tend to be much higher in oral contraceptive preparations.